Podcasts about Forte

In this episode of the LIFTS podcast, hosts Matthew Januszek and Mohammed Iqbal sit down with Lauren Foundos, founder of Forte (recently acquired by Echelon Fitness). Lauren shares her journey from Wall Street bond trading to becoming a pioneer in digital fitness, her lessons from building Forte, and her insights on the future of the fitness industry. Highlights: - How Lauren transitioned from Wall Street to fitness entrepreneurship. - The early challenges of selling digital fitness before gyms were ready. - Lessons learned from building and rebuilding fitness tech. - How content drives engagement and performance in gyms. - Why personal training is undervalued and how to fix it. - The explosive growth of Pilates and low-impact workouts. - How wearables and AI are reshaping fitness engagement. - The power of intellectual property in fitness tech. - Predictions for the future of gyms, training, and consumer behavior.

Dans cet épisode, je partage avec toi mon parcours de professeure de français au Mexique et aux États-Unis, dans différentes écoles de langues.Je t'explique pourquoi j'ai quitté ce système : classes trop nombreuses, manque d'éthique pédagogique, professeurs parfois peu formés et programmes pas adaptés aux vrais besoins des apprenants.Forte de cette expérience, j'ai décidé de créer ma propre méthode : Ta voix française. Une approche qui place l'apprenant au centre, qui favorise la pratique à l'oral, la confiance en soi et la fluidité.Si tu veux progresser en français, trouver ta voix française et enfin parler avec aisance, cet épisode est pour toi !`Bonne écoute,Virginie d'ehoui!----------------------------------------------------------------------------------Les 40 erreurs à NE PLUS faire, c'est gratuit et c'est ici.Tu veux enfin passer à la vitesse supérieure ? Prends des cours avec moi, c'est ici.Le club de lecture de roman policier, c'est ici.Un dollar fait la différence pour sauver les chiens et chats errants au Mexique, fais un don.

“Welcome back to the Driven By Details Podcast. Today's episode is a special one — and our longest yet. Almost two hours of unfiltered conversation packed with insights, stories, and lessons you won't want to miss.We dive deep into Gabe Madina background in detailing! Covering everything from how he got into the industry to events that led him down the road to Entrepreneurship , and even some behind-the-scenes experiences that most people never get to hear about.If you're passionate about detailing, business, or just love hearing real conversations from people in the industry, this episode is worth every minute. Buckle up — this one goes the distance.”

Ready to slow down and explore music in a whole new way? Join Ms. Elizabeth, Forte the Lion, and our very slow (but very sweet!) friend Adagio the Tortoise as we learn about tempo — how music can be slow like adagio or super fast like presto! With playful characters, guided movement, original songs, and a silly musical game, this episode will help your child feel the speed of music in their body and their imagination.

REDIFF - Ce vendredi 15 août 2025 marque l'ouverture du Championnat de France des échecs, à Vichy. Mais au fait, pourquoi la Reine est-elle plus forte que le Roi aux échecs ? Dans "Ah Ouais ?", Florian Gazan répond en une minute chrono à toutes les questions essentielles, existentielles, parfois complètement absurdes, qui vous traversent la tête.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Au menu de l'actualité :

This episode deep dives into the masculine and feminine, energetically, hormonally and culturally. Adriana Forte (LinkedIn, C-lab Substack) brings depth and philosophical rigour as well as the latin perspective to Amits Icelandic, masculine Nordic one. We speak of what a dance between the masculine and feminine may lead to, we speak of hormonal rhythms and torrents. We speak of just how much of women is left discarded in modernity. We speak of grief and the potential that may be unlocked when men stay and women step out. This conversation is potentially transformational. It is excellent an it is pointing at one of the core problems of our 

Naissances nomades a été créée par Marion Daron, une conjointe suiveuse établie au Congo-Brazzaville depuis dix ans. Sage-femme de formation et mère de cinq enfants nés sur trois continents – l'Asie, l'Europe et l'Afrique –, elle a travaillé à Londres et aux Philippines avant d'arriver en Afrique. Forte de cette expérience, elle décide de lancer Naissances nomades, il y a un an à Pointe-Noire au Congo. Rediffusion du 22 septembre 2024

Calciomercato e Ritiri con Marco Piccari e Lucio Marinucci. Ospiti: Tenerani:" La Fiorentina due obiettivi la Conference e 5 posto in campionato" Di Napoli: " Considero l'Inter forte, Chivu preparato con una società solida."

Me siga nas redes sociais: Facebook: Diego Menin Instagram: @diegonmenin Youtube: Diego Menin Twitter: @diegonmenin Site: www.diegomenin.com

durée : 00:10:39 - L'invité de 7h50 - par : Alexis Morel - Sophie Kervran, Directrice du musée de Pont-Aven et du musée de la pêche de Concarneau, est l'invitée du 7h50 pour parler de l'exposition "Sorcière 1860-1920, fantasme, savoir, liberté", présentée jusqu'au 16 novembre au musée de Pont-Aven. - invités : Sophie Kervran - Sophie Kervran : Directrice du musée de Pont-Aven et musée de la Pêche de Concarneau Cornouailles Agglomération Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

durée : 00:10:39 - L'invité de 7h50 - par : Alexis Morel - Sophie Kervran, Directrice du musée de Pont-Aven et du musée de la pêche de Concarneau, est l'invitée du 7h50 pour parler de l'exposition "Sorcière 1860-1920, fantasme, savoir, liberté", présentée jusqu'au 16 novembre au musée de Pont-Aven. - invités : Sophie Kervran - Sophie Kervran : Directrice du musée de Pont-Aven et musée de la Pêche de Concarneau Cornouailles Agglomération Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Olfa Zéribi est une universitaire tunisienne chevronnée, spécialiste du management stratégique et de l'innovation. Titulaire d'un doctorat en sciences de gestion de l'IGR‑IAE Rennes (France), elle enseigne depuis 2005 à l'Institut des Hautes Études Commerciales de l'Université de Carthage. Forte de près de 30 ans d'expérience dans l'enseignement supérieur, elle a occupé plusieurs postes de direction, notamment celui de directrice de l'école doctorale et fondatrice du master en management et stratégie. Elle a également été impliquée dans des projets européens tels que le programme Tempus « DICAMP » et, entre 2017 et 2020, a dirigé le programme Horizon 2020 pour le Ministère tunisien de l'Enseignement supérieur, jouant un rôle clé dans l'intégration de la Tunisie dans l'Espace européen de la recherche. En parallèle, elle a été consultante pour des institutions internationales comme le PNUD, la GIZ et l'UNESCO. Depuis septembre 2020, elle est directrice de la Direction Europe de l'Ouest de l'Agence universitaire de la Francophonie (AUF), où elle pilote les relations avec les établissements francophones et les initiatives de diplomatie scientifique. Elle a reçu la Médaille de l'Ordre du Mérite National en 2019 pour son engagement exceptionnel dans le domaine de l'éducation et de la recherche.Site web de l'AUF : https://www.auf.org/Site de la Direction régionale Europe Occidentale de l'AUF : https://www.auf.org/europe-ouest/Stratégie de l'AUF 2021-2025 : https://www.auf.org/wp-content/uploads/2017/03/Strate%CC%81gie-2021-2025.pdfLivre blanc de la francophonie scientifique (synthèse des résultats de la Consultation mondiale de la francophonie scientifique et socle de la Stratégie 2021-2025) : https://www.calameo.com/auf/read/0061183914d084f069e3a?page=1Le Manifeste pour une Diplomatie Scientifique Francophone : https://www.calameo.com/auf/read/006118391da441b2b228d

Send us a textTano and Nicole, the founders behind Bono Events International, share secrets about Tuscany and Umbria, neighboring regions in the heart of Italy. We start with Tuscany's iconic rolling vineyards, coastal fishing villages, great cities including Florence and Siena, and magnificent art scene and traditions.Then we focus on Umbria's rich religious heritage in Assisi, forested landscape, hilltop towns including Perugia, and captivating festivals. You'll find ruins dating from Roman Times, and even unexpected waterfalls. From the picturesque coasts of Forte dei Marmi to the the walls of Lucca to the flowers of Spello; from the great cathedral in Orvieto to the leaning tower in Pisa, this episode is both informative and enchanting -- with lots of surprises.Guests Tano and Nicole, the founders behind Bono Events International, live in Italy.**Podcast host Lea Lane has traveled to over 100 countries, and  has written nine books, including the award-winning Places I Remember  (Kirkus Reviews star rating, and  'one of the top 100 Indie books of  the year'). She has contributed to many guidebooks and has written thousands of travel articles. _____Our award-winning travel podcast, Places I Remember with Lea Lane, has dropped over 120 travel episodes! New episodes drop on the first Tuesday of the month, on Apple, Spotify, and wherever you listen. _____Travel vlogs of our featured  podcasts-- with video and graphics -- now drop on YouTube . Please subscribe, like, and comment. ****************************************Substack: Lane ChangesWebsite: https://placesirememberlealane.com Travel Blog: forbes.comBlueSky: lealane.bsky.socialX (Twitter):@lealane Instagram: PlacesIRemember

Il faut parfois se méfier des enseignements d'une seule saison. Mais avec un retour en playoffs, et même une qualification en finale de conférence NFC, les Washington Commanders ont surpassé les espérances, pour la première année du head coach Dan Quinn et du quarterback Jayden Daniels aux manettes.Ce succès est-il parti pour durer, dans une conférence nationale relativement ouverte ? Gregory Richard et Victor Roullier en débattent pour l'occasion.Bonne écoute ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

In this episode of America on the Road, host Jack Nerad and co-host Chris Teague discuss the latest automotive news, including new tax breaks for car buyers, challenges faced by important global automakers, and exciting new vehicle releases from GMC and Mercedes-Benz. They also provide in-depth reviews of the 2025 Kia K4 sedan and the 2025 Lexus IS 500 F Sport Performance, highlighting their features and performance. In this week's road test segment, host Jack Nerad discovers the 2025 Lexus IS 500 F Sport Performance to be a breath of fresh air in today's highly homogenized and shrinking sedan market. With a 472-horsepower naturally aspirated V8 under its hood, this unassumingly styled rear-wheel-drive sedan blends old-school performance with modern tech and refinement. Aggressively tuned for back-road thrills yet wrapped in a sleek, understated four-door package, the IS 500 offers a visceral experience, enhanced by high-end features like heated/ventilated sport seats, a Mark Levinson sound system, and a refined tech suite. And you'll never guess the cars Jack Nerad compares it to. Also in the spotlight this week is Chris Teague's test of the all-new 2025 Kia K4, a compact sedan aiming to shake up the segment with bold styling and surprising tech. Replacing the outgoing and under-rated Forte, the K4 pulls into the lot with a surprisingly upscale interior, available turbocharged power, and Kia's latest infotainment platform. Chris dives into how it drives, how it stacks up against rivals like the Honda Civic and Toyota Corolla, and whether Kia has another budget-friendly hit on its hands. This episode's special guest is Anthony Monaco, marketing lead for Ram heavy-duty trucks. Monaco joins the show to discuss exciting and affordable new product updates from Ram, shedding light on where the brand is heading and what consumers can expect from the latest heavy-duty lineup. In the news, a sweeping new federal tax deduction could shake up the auto financing world. Under the “Big, Beautiful Bill” signed by President Trump, qualifying buyers can now deduct up to $10,000 in interest on loans for U.S.-assembled vehicles. The catch? Income caps apply, leases are excluded, and not every car will qualify. The IRS will release a list of eligible models, and VIN documentation will be required. Is it a good idea? We'll have details. Meanwhile, three major global automakers—Stellantis, Porsche, and Jaguar Land Rover—are navigating rocky terrain. Stellantis reported a staggering $2.7 billion loss, tied to new tariffs and slumping sales, while Porsche is slashing costs amid weakening EV demand. JLR, reeling from a 15% sales dip and delayed EV rollouts, is trimming jobs and recalibrating its strategy. Two big product debuts also made headlines. GMC launched the 2026 Acadia Denali Ultimate, pushing deeper into luxury with full-leather interiors, Super Cruise hands-free driving, and a 16-speaker Bose system. At the same time, Mercedes-Benz revealed its next-gen CLA, available first in battery-electric and then hybrid form. The EV variant boasts nearly 500 miles of range and impresively fast charging, while the hybrids promise efficiency and flexibility for mainstream buyers. This episode also highlights the America on the Road Made in America Tour, which showcases vehicles and other products built in the U.S., tying in with new buyer incentives and celebrating American ingenuity and homegrown manufacturing. We close the show with a listener question from Mitchell in Boulder, Colorado, who says, “I want to buy a new car, but I need some help in making the deal. How much should I negotiate off the MSRP on a new car?” Jack and Chris share advice on negotiation strategy, dealer incentives, and the current state of new car pricing. Check Out Matt's Book: Pick up a copy of co-host Matt DeLorenzo's terrific new book How to Buy an Affordable Electric Car: A Tightwad's Guide to EV Ownership.

Dans cette édition : Affluence sur les routes de France pour ce grand week-end de chasse et de départs en vacances, avec des prévisions de trafic chargé sur les axes autoroutiers. Forte activité dans les garages pour les derniers réglages des véhicules avant le départ en vacances. Augmentation des noyades mortelles en juillet en France, avec 700 noyades recensées et 193 décès, liée aux fortes températures. Réaction du ministre Jean-Noël Barrot sur l'accueil en France d'une étudiante gazaoui aux propos antisémites, avec l'annonce du gel de toute nouvelle arrivée de Gazaouis. Hausse des droits de douane américains, impactant notamment l'industrie cosmétique française qui craint des pertes de 300 millions d'euros et 5000 emplois. Bilan mitigé pour le secteur du tourisme en France à mi-parcours de l'été, avec une baisse de fréquentation et de pouvoir d'achat des clients. Prévisions météorologiques contrastées pour le week-end, avec un temps ensoleillé dans le sud mais des averses et orages dans le nord-est.   Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition : Affluence sur les routes de France pour ce grand week-end de chasse et de départs en vacances, avec des prévisions de trafic chargé sur les axes autoroutiers. Forte activité dans les garages pour les derniers réglages des véhicules avant le départ en vacances. Augmentation des noyades mortelles en juillet en France, avec 700 noyades recensées et 193 décès, liée aux fortes températures. Réaction du ministre Jean-Noël Barrot sur l'accueil en France d'une étudiante gazaoui aux propos antisémites, avec l'annonce du gel de toute nouvelle arrivée de Gazaouis. Hausse des droits de douane américains, impactant notamment l'industrie cosmétique française qui craint des pertes de 300 millions d'euros et 5000 emplois. Bilan mitigé pour le secteur du tourisme en France à mi-parcours de l'été, avec une baisse de fréquentation et de pouvoir d'achat des clients. Prévisions météorologiques contrastées pour le week-end, avec un temps ensoleillé dans le sud mais des averses et orages dans le nord-est.   Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Katie Trevena, a senior vice president for real estate advisory at Forte Real Estate Partners talks to F&C reporter Dan Netter. Trevena talks about the office and health care leasing market and about her work as a Chanhassen planning commissioner.

Un violento terremoto di magnitudo 8.8 ha colpito la penisola della Kamchatka, in Russia, nella notte di oggi 30 luglio, con epicentro a circa 136 km dalla città di Petropavlovsk-Kamchatsky e a una profondità di 20.7 km, generando onde di tsunami che hanno raggiunto le Hawaii, la California, il Giappone e le coste del Pacifico. Si tratta del sesto terremoto più violento mai registrato nella storia e il più forte rilevato nella zona dal 1952, causato dalla subduzione della placca pacifica sotto quella nordamericana. Ma perché è stato così forte? E come si genera uno tsunami dopo un terremoto? In questo video analizzeremo insieme a Stefano Gandelli le cause geologiche e il funzionamento della Cintura di Fuoco del Pacifico, la zona del Pianeta in cui ci sono più vulcani e più terremoti al mondo. Prendi parte alla nostra Membership per supportare il nostro progetto Missione Cultura e diventare mecenate di Geopop: https://geopop.it/Muh6X Learn more about your ad choices. Visit megaphone.fm/adchoices

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I am interviewing Dr. Nikhil Munshi on the “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” by Avet-Loiseau et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. While some patients with multiple myeloma live for decades after treatment, others exhibit refractory or rapidly relapsing disease irrespective of treatment administered. We term this “high-risk myeloma.” Multiple risk stratification systems have been created, starting with the Durie-Salmon system in 1975 and evolving with the advent of novel therapeutics and novel treatment approaches. In 2015, the Revised International Staging System (R-ISS) was introduced, which incorporated novel clinical and cytogenetic markers and remained, until recently, a mainstay of risk stratification in newly diagnosed disease. Myeloma as a field has, just in the past few years, though, undergone explosive changes. In particular, we have seen groundbreaking advances not only in treatments - the introduction of anti-CD38 agents and the advent of cellular and bispecific therapies - but also in diagnostic technology and our understanding of the genetic lesions in myeloma. This has led to the proliferation of numerous trials employing different definitions of high-risk myeloma, a burgeoning problem for patients and providers alike, and has prompted attempts to consolidate definitions and terminology. Regarding cytogenetic lesions, at least, Kaiser et al's federated meta-analysis of 24 therapeutic trials, published here in the JCO in February of 2025 and recently podcasted in an interview with associate editor Dr. Suzanne Lentzsch, posited a new cytogenetic classification system to realize a shared platform upon which we might contextualize those trial results. This article we have here by Dr. Avet-Loiseau, Dr. Munshi, and colleagues, published online in early June of this year and hot off the presses, is the definitive joint statement from the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG). What is high-risk multiple myeloma for the modern era? The IMS and IMWG Genomics Workshop was held in July 2023 and was attended by international myeloma experts, collaborating to reach consensus based on large volumes of data presented and shared. The datasets included cohorts from the Intergroupe Francophone du Myélome (IFM); the HARMONY project, comprised of multiple European academic trials; the FORTE study, findings from which solidified KRd as a viable induction regimen; the Grupo Español de Mieloma Múltiple (GEM) and the PETHEMA Foundation; the German-Speaking Myeloma Multicenter Group (GMMG); the UK-based Myeloma XI, findings from which confirmed the concept of lenalidomide maintenance; Emory 1000, a large, real-world dataset from Emory University in Atlanta; the Multiple Myeloma Research Foundation Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) dataset; and some newly diagnosed myeloma cohorts from the Mayo Clinic. Data were not pooled for analyses and were assessed individually - that is to say, with clear a priori understanding of whence the data had been gathered and for what original purposes. Consensus on topics was developed based on the preponderance of data across studies and cohorts. In terms of results, substantial revisions were made to the genomic staging of high-risk multiple myeloma, and these can be sorted into three major categories: A) alterations to the tumor suppressor gene TP53; B) translocations involving chromosome 14: t(14;16) (c-MAF overexpression), t(14;20) (MAFB overexpression), and t(4;14) (NSD2 overexpression); and C) chromosome 1 abnormalities: deletions of 1p or additional copies of 1q. In terms of category A, TP53 alterations: Deletion of 17p is present in up to 10% of patients at diagnosis and is enriched in relapsed or refractory disease. This is well-documented as a high-risk feature, but the proportion of the myeloma cells with deletion 17p actually impacts prognosis. GEM and HARMONY data analyses confirmed the use of 20% clonal cell fraction as the optimal threshold value for high-risk disease. That is to say, there must be the deletion of 17p in at least 20% of the myeloma cells on a FISH-analysis of a CD138-enriched bone marrow sample to qualify as high-risk disease. TP53 mutations can also occur. Inactivating mutations appear to have deleterious effects similar to chromosomal losses, and the biallelic loss of TP53, however it occurs, portends particularly poor prognosis. This effect is seen across Myeloma XI, CoMMpass, and IFM cohorts. Biallelic loss is rare, it appears to occur in only about 5% of patients, but next-generation sequencing is nevertheless recommended in all myeloma patients. Category B, chromosome 14 translocations: Translocation t(14;16) occurs in about 2% to 3% of patients with newly diagnosed disease. In the available data, primarily real-world IFM data, t(14;16) almost always occurs with chromosome 1 abnormalities. Translocation t(4;14) occurs in about 10% to 12% of newly diagnosed disease, but only patients with specific NSD2 alterations are, in fact, at risk of worse prognosis, which clinically appears to be about one in every three of those patients. And so together, the CoMMpass and Myeloma XI data suggest that translocation t(4;14) only in combination with deletion 1p or gain or amplification of 1q correlates with worse prognosis. Translocation t(14;20) occurs in only 2% of newly diagnosed disease. Similar to translocation t(4;14), it doesn't appear to have an effect on prognosis, except if the translocation co-occurs with chromosome 1 lesions, in which case patients do fare worse. Overall, these three translocations - t(14;16), t(4;14), and t(14;20) - should be considered high-risk only if chromosome 1 aberrations are also present. In terms of those chromosome 1 aberrations, category C, first deletions of 1p: Occurring in about 13% to 15% of newly diagnosed disease, deletion 1p eliminates critical cell checkpoints and normal apoptotic signaling. In the IFM and CoMMpass dataset analyses, biallelic deletion of 1p and monoallelic deletion of 1p co-occurring with additional copies of 1q denote high-risk. In terms of the other aberration in chromosome 1 possible in myeloma, gain or amplification of 1q: This occurs in up to 35% to 37% of newly diagnosed disease. It upregulates CKS1B, which is a cyclin-dependent kinase, and ANP32E, a histone acetyltransferase inhibitor. GEM and IFM data suggest that gain or amplification of 1q - there was no clear survival detriment to amplification - is best considered as a high-risk feature only in combination with the other risk factors as above. Now, in terms of any other criteria for high-risk disease, there remains one other item, and that has to do with tumor burden. There has been a consensus shift, really, in both the IMS and IMWG to attempt to develop a definition of high-risk disease which is based on biologic features rather than empirically observed and potentially temporally dynamic features, such as lactate dehydrogenase. Beta-2 microglobulin remains an independent high-risk indicator, but care must be taken when measuring it, as renal dysfunction can artificially inflate peripheral titers. The consensus conclusion was that a beta-2 microglobulin of at least 5.5 without renal failure should be considered high-risk but should not preclude detailed genomic profiling. So, in conclusion, the novel 2025 IMS-IMWG risk stratification system for myeloma is binary. It's either high-risk disease or standard-risk disease. It's got four criteria. Number one, deletion 17p and/or a TP53 mutation. Clonal cell fraction cut-off, remember, is 20%. Or number two, an IGH translocation - t(4;14), t(14;16), t(14;20) - with 1q gain and/or deletion of 1p. Or a monoallelic deletion of 1p with 1q additional copies or a biallelic deletion of 1p. Or a beta-2 microglobulin of at least 5.5 only when the creatinine is normal. This is a field-defining work that draws on analyses from across the world to put forward a dominant definition of high-risk disease and introduces a new era of biologically informed risk assessment in myeloma. Now, how does this change our clinical approach? FISH must be performed on CD138-enriched samples and should be performed for all patients. Next-generation sequencing should also be performed on all patients. Trials will hopefully now begin to include this novel definition of high-risk multiple myeloma. It does remain to be seen how data from novel therapeutic trials, if stratified according to this novel definition, will be interpreted. Will we find that therapies being evaluated at present have differential effects on myelomas with different genetic lesions? Other unanswered questions also exist. How do we go about integrating this into academic and then community clinical practice? How do we devise public health interventions for low-resource settings? To discuss this piece further, we welcome the esteemed Dr. Nikhil Munshi to the podcast. Dr. Munshi is a world-renowned leader in multiple myeloma and the corresponding author on this paper. As Professor of Medicine at Harvard Medical School, Director of the Multiple Myeloma Effector Cell Therapy Unit, and Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, he has presided over critical discoveries in the field.  Thank you for joining us, Dr. Munshi. Dr. Nikhil Munshi: Oh, it's my pleasure being here, Michael, to discuss this interesting and important publication. Michael Hughes: I had a few questions for you. So number one, this is a comprehensive, shall we say, monumental and wide-ranging definition for high-risk myeloma. How do you hope this will influence or impact the ways we discuss myeloma with patients in the exam room? And how do we make some of these components recommended, in particular next-generation sequencing, feasible in lower-resource settings? Dr. Nikhil Munshi: So those are two very important questions. Let's start with the first: How do we utilize this in our day-to-day patient care setting? So, as you know well, we have always tried to identify those patients who do not do so well with the current existing treatment. And for the last 30 years, what constitutes a myeloma of higher risk has continued to change with improvement in our treatment. The current definition basically centers around a quarter of the patients whose PFS is less than 2 to 3 years. And those would require some more involved therapeutic management. So that was a starting point of defining patients and the features. As we developed this consensus amongst ourselves - and it's titled as “International Myeloma Society, International Myeloma Working Group Consensus Recommendation” - this IMS-IMWG type of recommendation we have done for many years, improvising in various areas of myeloma care. Now, here, we looked at the data that was existing all across the globe, utilizing newer treatment and trying to identify that with these four-drug regimens, with transplant and some of the immunotherapy, which group of patients do not do as well. And this is where this current algorithm comes up. So before I answer your question straight, “How do we use it?” I might like to just suggest, “What are those features that we have identified?” There are four features which constitute high-risk disease in the newer definition. Those with deletion 17p with 20% clonality and/or TP53 mutation. Number two, patients with one of the translocations - t(4;14), t(14;16), or t(14;20) - co-occurring with 1q amplification or deletion 1p32. And that's a change. Previously, just the translocation was considered high-risk. Now we need a co-occurrence for it to be called high-risk. The third group is patients having biallelic deletion 1p32 or monoallelic deletion 1p32 along with 1q amplification. And finally, patients with high beta-2 microglobulin, more than or equal to 5.5 mg/dL, with normal creatinine less than 1.2 mg/dL. And the question, “How do we use this?” There are multiple areas where we incorporate high-risk features in our treatment algorithm. One of the first areas is where we would consider the induction regimen. If a patient has a high-risk disease, we would definitely consider a four-drug regimen rather than a three-drug regimen, although we are beginning to incorporate four-drug for all groups. That's one important thing. Number two, those are the patients where we do consider consolidation with transplant or maybe in the new world, considering some of the immunotherapeutic consolidation more early or more aggressively. Number three, these are the patients who get a little bit more maintenance therapy. So normally, lenalidomide might end up being our standard maintenance regimen. In patients who have high-risk disease, we incorporate either addition of daratumumab or the anti-CD38 targeting antibody and/or addition of proteasome inhibitor, either bortezomib or carfilzomib. So you would have multi-drug maintenance therapy in these patients. And in high-risk patients, we follow them with maintenance longer periods of time. One very critically important point to keep in mind is that to get the better outcome in high-risk disease, we must try to get them into MRD negativity because there is clear data that patients who do achieve MRD negativity, despite having high-risk disease, have a much superior outcome. They become near to standard-risk disease. And so, in high-risk patients, I would try to do whatever various options I have to try and get them into MRD-negative status. And when these patients relapse, we do not wait for the classic progression criteria to be met before we intervene. We would propose and suggest that we intervene earlier before the disease really blasts off. And so there are a number of areas in our setting where this high-risk definition will help us intervene appropriately and also with appropriate aggressiveness to achieve better outcome, to make this similar to standard-risk disease. Michael Hughes: Thank you, Dr. Munshi. And thoughts on how to really integrate this not only into academic centers but also lower-resource settings? Dr. Nikhil Munshi: So that's a very important question, Michael. And when we were developing this consensus, we were very cognizant of that fact. So wherever available, I think we are recommending that over a period of next 2, 3, 5 years, we should begin to switch over to sequencing-based methods because two components of this definition, one is TP53 mutation, which we cannot do without sequencing, and also reliably detecting deletion 1p requires sequencing-based method. So in the low-resource countries - and there are many in this world, and also even in our own country, patients may not be able to afford it - the older method with FISH or similar such technology, which is more affordable, is also acceptable for current time. They may miss a very small number of patients, maybe 2% to 3%, where these finer changes are not picked up, but a majority of this would be captured by them. So the current practice might still be applicable with some limitation in those patient populations, and that's what we would recommend. What is happening, fortunately, is that actually sequencing-based method is becoming cheaper. And in many centers, it is cheaper to do the sequencing rather than to do the FISH analysis. And so my hope is that even in low-resource centers, sequencing might be more economical in the end. It's, I think, the access to technology, which is a little bit limited currently, but it's hopefully becoming available soon. Michael Hughes: Thank you, Dr. Munshi. And staying for a minute and looking at the multiple myeloma subsets which might be missed by this really still very broad-ranging high-risk definition, at least by prior risk stratification systems, right, there is this group of patients who have standard-risk cytogenetics by R-ISS or R2-ISS, but they have primary refractory disease or they relapse early. We call these, as you are well aware, functionally high-risk disease. What proportion of previously FHR, functionally high-risk, myeloma patients do you expect to be captured by this novel definition? Dr. Nikhil Munshi: So I think the newer definition - and we can look at it both ways, but the newer definition should capture most of the functionally high-risk definition. To put it differently, Michael, there are patients who we know are, as you mentioned, functionally high-risk. Those are the patients who might have plasma cell leukemia, those who might have extramedullary disease, those who might not respond to our four-drug induction. If you don't respond to the four-drug induction, almost by definition, they are high-risk. However, a majority of them have one of the abnormalities that we are describing here. There would be a very small proportion which may not have. And if they do not have, we know one of the important components of this definition here is also that the genome, we know, keeps on evolving. So there may be a very small clone with the high-risk feature which was not obvious in the beginning. Following treatments or following relapse, that clone predominates, and now the patient's disease becomes high-risk.  So the definition would incorporate or would capture these functional high-risk patients, but as you said, in countries where resources are not available, using this functional high-risk would also be helpful and advantageous. Sometimes LDH ends up being a high-risk. In our studies, LDH has not come out to be high-risk anymore because the features we are describing captures most of those patients, but those alternatives, older, can still be considered if other newer techniques are not available. Michael Hughes: Got you. And in terms of these older definitions, yes, that incorporate tumor burden, these empirical observations about how myeloma presents, do you foresee any additional tumor burden indicators being added to future definitions of high-risk disease? Or do you instead see this particular definition as a major waypoint on the journey towards a fully biologically grounded definition of high-risk disease? Dr. Nikhil Munshi: I think your second part is what is going to happen. I think the tumor burden-related definition is being now replaced by the biological or genomic-based definition. And I think at some point, it will be quite fully replaced. One component not here, and it is because one thing, we don't have enough data; number two, we don't know how it will pan out, is also the influence of the microenvironment on the risk definition. For example, the immune system, the immune function, etc. But not enough data exists to suggest how it would change the current definition. So in future, would a definition be totally genomic or it could be more integrative? And my personal guess is that it would be more integrative and that some immune features might come into the picture, especially now that we are using immune-based therapy as a very important component of treatment - CAR T-cells, bispecific, and antibody-based treatments. What role the immune system plays in either supporting tumor or what role suppression of the anti-tumor immunity plays? They all will be important how patient outcomes end up being, and which in turn could translate into how patient's risk stratification might happen. So I think the older tumor burden-related definitions probably will become things of the past. What we have currently proposed and consensus developed is the new path forward, and over time, some microenvironmental influences, if defined and found to be important, may get some more incorporation if it compares favorably with the genomic features. Michael Hughes: Thank you, Dr. Munshi for that enlightening response.  To conclude the podcast, I'd like to look to the future and to the immediate future, what are the next steps for high-risk disease definition between now and discussing an integrated genomic-microenvironment-based definition? Will we see attempts to refine? Will we see a multi-level system, things like this? Dr. Nikhil Munshi: Yeah, so I think the current definition will be here to stay for the next 10 years or so. I think this has been developed using a large amount of data, so we do believe that this will remain fine. It has been validated now within the last six months by a few of the other studies. So there won't be a quick change. But we will try to, all of us will try to innovate. And as you very rightly bring up, the areas of research would include looking at the expression or transcriptomic component. Does that matter? And we do believe a small number of patients will have transcriptomic changes, not looked at the DNA changes, and may play a role. There are newer components, so long non-coding RNA, for example, is going to be an important component to look at, how it impacts the disease outcome, etc. There are also some of the proteomic-related changes which may become important in our studies. And then as we discussed, microenvironment and immunological changes. So these are the future areas of ongoing research where we all should collect data, and then in the next 5 to 10 years, we'll have another group meeting to see has anything changed or any of the features have become more important.  Most of the time, some of the older features are lost because they are not as critically high-risk, and the newer features come in. And so the historical background for just one second, there was a time when chromosome 13 was considered a high-risk disease. We now don't even mention it because it's not high-risk. The newer treatments have improved the outcome. t(4;14) used to be a high-risk disease. Now by itself today, in this definition by itself is not; it needs to be with something else. And so I think this is a great sign of progress. As we improve the treatment and outcomes, some of the features will become less important, new features will come up, and we'll need to keep on evolving with time and with technology and make it better for patients. Michael Hughes: Thank you so much, Dr. Munshi, for your wisdom, for your sagacity, for your historical perspective as well.  Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries. And be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

MINIMAL CLUB, USE O CUPOM "BRUNET" https://djfy.short.gy/S8TLCUConferência Destino: https://conferenciadestino.com.br/Como fortalecer o casamento, prosperar em casal e alinhar fé, negócios e propósito? Neste episódio do Brunecast, exploramos com profundidade os desafios e os segredos por trás de um relacionamento duradouro e bem-sucedido.✅ Descubra como a comunicação, o alinhamento espiritual e o empreendedorismo podem transformar sua vida a dois.✅ Entenda por que tantos casais se perdem no meio do caminho e como evitar isso.✅ Receba conselhos práticos sobre limites familiares, criação de filhos, intimidade, rotina e tomadas de decisão em conjunto.Com participação dos consultores teológicos Theo e Olo, garantimos que tudo está alinhado aos princípios bíblicos e espirituais.

Will Forte talks about almost being a financial advisor, his checkered writing career, SNL MacGruber, Nebraska, The Groundlings, Last Man on Earth, having kids late, seeing shrinks, frats, & Val Kilmner being the weirdest roommate of all time.Bio: Will Forte is a comedian, actor, writer, and improviser best known for his work on Saturday Night Live and his starring role in The Last Man on Earth. Born in Alameda County, California, Forte studied History at UCLA before briefly working as a financial broker. He shifted to comedy in the late '90s, joining the Groundlings and writing for shows like The Jenny McCarthy Show and That '70s Show. His pilot about two clueless brothers led to The Brothers Solomon (2007), which he wrote and starred in. Forte joined Saturday Night Live in 2002, quickly earning a reputation for absurd and surreal comedy. He co-wrote and starred in the cult film MacGruber (2010) before leaving SNL to pursue broader roles. He appeared in comedies like 30 Rock, Tim and Eric's Billion Dollar Movie, and That's My Boy, while also branching into drama with Run and Jump and Alexander Payne's Nebraska (2013), earning critical praise. From 2015 to 2018, he created and starred in the acclaimed sitcom The Last Man on Earth. He later portrayed Douglas Kenney in A Futile and Stupid Gesture (2018) and appeared in hit films like Booksmart and Good Boys (2019). More recently, he has starred in Netflix's Bodkin, Four Seasons, and the upcoming Coyote vs. Acme.

No episódio de hoje, Zé Márcio conversa com o economista Cláudio Frischtak, presidente da Inter.B Consultoria, sobre um dos principais entraves ao desenvolvimento do Brasil: a insegurança jurídica. Frischtak destaca como a falta de previsibilidade nas regras e decisões judiciais afasta investimentos, compromete a confiança dos agentes econômicos e atrasa o crescimento do país.

We back. Presented by the Garza Law Firm. For the full episode, go to Patreon.com/ReedsRanch. Vols at SEC Media Days, QB Battle, Nate Ayyyyyyyyyyy-ment.

Romanos 9:14–18 apresenta uma verdade profunda, desafiadora — e gloriosa: Deus é soberano. Ele tem misericórdia de quem quer, e endurece a quem quer. Para alguns, essa doutrina parece injusta. Mas, para os que conhecem o caráter de Deus, ela é uma fonte de reverência, adoração e descanso. Neste episódio, Paulo responde a uma pergunta inevitável: “Há injustiça da parte de Deus?” E sua resposta é enfática: “De modo nenhum!” A eleição soberana não nega a justiça de Deus — ela a revela. Deus não deve misericórdia a ninguém, mas, pela Sua graça, a concede a muitos. Prepare-se para mergulhar nas águas profundas da soberania divina. Este episódio não é para os fracos de coração — mas para os que estão prontos a dizer: “Deus está no trono.” Para mais ensinamentos bíblicos, visite nosso site: https://www.wisdomonline.org/?lang=Portuguese

Temperance! Divorce! Suffrage! Broken coffee cup! Makeouts in carriages! Clocks! Mediums! Questionable frocks! Sisters! Even more Broadway stars! An exciting season brings regime change at the Van Rhijn–er, Forte household, bold new opportunities for work and love for Peggy, and the culmination of the ultimate marriage plot! Will Peggy find true love with the Hot Doctor, or will his snooty mama get in the way? Will the new Duchess triumph? Is the Russell marriage in trouble? Is Larry a cad or just clueless about public canoodling? Will Bertha's sister Monica stick around (even if she does dress like the cook on her day off)? Will Hector's creepy sister pull a Mrs. Danvers? And most importantly, will our dear Jack find happiness now that he's worth a few mill? But wait there's more: Tune in for the Episodes 5-8 podcast in August Then the Downtown Abbey film podcast in September! Your hosts: Shannon Bowen https://instagram.com/theshannonbowen Therese Shechter https://instagram.com/trixiefilms Brandi Sperry https://www.instagram.com/oui_brandi/

Confira nesta edição do JR 24 Horas: As chuvas intensas atingiram a região nordeste dos Estados Unidos, afetando especialmente os estados de Nova York, Nova Jersey e Pensilvânia. O serviço de metrô foi suspenso em partes de Nova York devido ao alagamento que invadiu os vagões. Algumas linhas apresentaram atrasos por conta das enchentes nas estações. E ainda: Começa a valer ultimato dado por Donald Trump para que Rússia chegue a um acordo de cessar-fogo com a Ucrânia.

Dans ce nouvel épisode d'Insight, nous recevons Solène Madec, fondatrice et CEO de l'Agence Belle. Avec nous, elle revient sur l'évolution de l'agence, passée de partenaire des scale-ups à référence pour des marques patrimoniales comme Gifi, Flunch, TF1 ou Gallia. Forte de son expérience chez l'annonceur, elle défend une approche alliant créativité et efficacité business, en cassant la fausse opposition entre performance et brand. Loin d'êtres opposées, ou incompatibles, elle nous explique combien ces deux approches se répondent, se complètent, et s'enrichissent. Alors, cette idée reçue est-elle encore prégnante dans l'imaginaire collectif ? Quels freins empêchent encore les annonceurs de voir la créativité comme vectrice de performance business ? Comment s'organiser en interne pour garantir cette alchimie entre idée forte et efficacité mesurable, alors même que les budgets se durcissent ? Elle nous répond !Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Invité : - Laurent Nuñez, Préfet de police de Paris Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Maracanà con Marco Piccari e Stefano Impallomeni. Ospiti: Capua:" Sarri fa bene a parlare di campo." Volpi:"Lookman più da Barcellona. La rosa della Lazio è importante" Bonanni" Valhovic non è da top club. La Lazio deve partire forte"

Família chalupas e traições absurdas.

From tattoos to tackle, Anthony Forte is a well-experienced charter captain out of Boston and catches them "two tree at a time". Forte talks about how he got into fishing, along with his side of Cheech's white marlin story.

C'è chi desidera avere una personalità più forte e chi mente, dice spesso un mio amico. La verità è che il tema della personalità è molto delicato e la vera forza è spesso molto diversa da come la immaginiamo. In questo episodio ti mostro come funziona la personalità, che cosa è per davvero e come puoi lavorarci…Clicca qui per approfondire (link attivo dalle 5:00 AM del 07/07/25) https://psinel.com/come-avere-una-personalita-davvero-forte/Sei Psicologa/o? Stiamo creando una squadra di professionisti partecipa al Sondaggio⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://newmanspirit.typeform.com/to/cq3TyGC1⁠⁠⁠⁠⁠⁠⁠⁠⁠Mindfitness è il nostro percorso gratuito per sviluppare il legame tra energia mentale e fisica. L'ho fatto insieme ad un grande professinista il dott. Valerio Rosso (medico psichiatra).⁠⁠⁠⁠⁠⁠⁠⁠⁠ Iscriviti gratis cliccando qui⁠⁠⁠⁠⁠⁠⁠⁠⁠Se ti piace il podcast adorerai il mio Nuovo libro: “Restare in piedi in mezzo alle Onde - Manuale di gestione delle emozioni”...⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://amzn.eu/d/1grjAUS⁠⁠⁠⁠⁠⁠⁠⁠⁠- Vuoi Imparare a Meditare? Scarica Gratis Clarity:⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://clarityapp.it/⁠⁠⁠⁠⁠⁠⁠⁠⁠- Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/gennaro_romagnoli/⁠⁠⁠⁠⁠⁠⁠⁠⁠- Test sull'Ansia: https://psinel.com/test-ansia-ig-pd/I NOSTRI PERCORSI:- Dall'Ansia alla Serenità:⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://psinel.com/ansia-serenita-sp/⁠⁠⁠⁠⁠⁠⁠⁠⁠- Emotional Freedom:⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://psinel.com/emotional-freedom-sp/⁠⁠⁠⁠⁠⁠⁠⁠⁠- Self-Kindness:⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://psinel.com/self-kindness-sp/⁠⁠⁠⁠⁠⁠⁠⁠⁠- MMA (Master in Meditazione Avanzata):⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://psinel.com/master-meditazione-avanzata-sp/⁠⁠⁠⁠⁠⁠⁠⁠⁠- Scrivi la Tua Storia:⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://psinel.com/scrivi-la-tua-storia-sp/- Self-Love: https://psinel.com/self-love-sp/⁠⁠⁠⁠⁠⁠⁠⁠⁠Credits (traccia audio): https://www.bensound.com

✅CUPOM 15-JOELJOTA: https://bit.ly/d2csummit-jjSegunda-feira não é só mais um dia. É o dia em que você mostra pra você mesmo quem comanda a sua vida.

Following the June 23 OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it's defined, and whether it's truly achievable.To watch the OX40 webinar, please click here.Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

No “Estadão Analisa” desta quinta-feira, 26, Carlos Andreazza comenta sobre a votação-surpresa que resultou na derrubada do aumento do IOF, nesta quarta-feira, 25, irritou auxiliares e aliados do presidente Luiz Inácio Lula da Silva, que anteveem instabilidade e desconfiança na relação com o presidente da Câmara, Hugo Motta (Republicanos-PB). Governistas não esperavam que fosse votado nesta semana o projeto que derruba o decreto presidencial de aumento do IOF, e relatam que Motta, até a noite de terça-feira, 24, não havia dado sinal algum de que o tema entraria na pauta do dia seguinte. Leia mais: https://www.estadao.com.br/economia/derrota-iof-escancara-relacao-instavel-governo-camara-e-alerta-proximas-votacoes/ Assine por R$1,90/mês e tenha acesso ilimitado ao conteúdo do Estadão. Acesse: https://bit.ly/oferta-estadao O 'Estadão Analisa' é transmitido ao vivo de segunda a sexta-feira, às 7h, no Youtube e redes sociais do Estadão. Também disponível no agregador de podcasts de sua preferência. Apresentação: Carlos AndreazzaEdição/Produção: Jefferson PerlebergCoordenação: Manuella Menezes e Everton OliveiraSee omnystudio.com/listener for privacy information.

William Norvell Co-Founder of Forte. Forte is the proactive mental fitness service strengthening culture through human connection, interactive resources, and actionable data. What I learned in my conversation with William. God is often a "yellow light" God, meaning that often times he gives us the freewill option to pursue our dreams and once we overcome our fears he gives us a green light. Traveling with meaningful partners in business ventures is essential. Every high-level leader needs a trusted guide who provides a space for mental safety. Build a red alert text chain of people who remind you of your true identity when life gets challenging. Build the list of your red alert people now. Therapy is great. However, oftentimes you simply need a mental fitness partner. Learn to spot the shadow mission of when life is only five degrees off. Contending for the Lord is good, but striving is a bridge to far. --To start working with Lantz as your professional coach, take the free health assessment at www.lantzhoward.com --Do you know an organization that would benefit from Forte?Share this episode with a friend that you care about. --Follow Lantz on LinkedIn.

This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children. To view the video version of this webinar, please click here. Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

Ready to cool off and laugh along? Join Ms. Elizabeth, Forte the Lion, and special guest Ruby for a refreshing summer-themed episode! We'll share a playful summer poem, explore the exciting music of Vivaldi's Summer, and dive into some sunny jokes that are sure to make your little ones giggle. Plus, we'll give you tips for writing your own jokes and invite you to download a fun printable that brings all the joy of this episode to life! What We'll Do in This Episode:– Hear Ruby recite the poem Open Hydrant by Marci Ridlon– Listen to music from Vivaldi's Summer and imagine a city waterfall in the heat– Explore how music and poetry can paint pictures in our minds Grab the Free Printable from This EpisodeIncludes the full poem, coloring page, tons of listening ideas for Vivaldi's Four Seasons Summer 2nd movement, bonus page of summer jokes and joke- writing guide!

This week, we have a very special episode of Nateland as the guys take the show on the road to visit the set of Nate's movie The Breadwinner. Nate, Brian, Aaron, and Dusty talk with some of the stars (Will Forte, Mandy Moore, Martin Herlihy, Charlotte Ann Tucker, Stella Grace Fitzgerald, & Birdie Borria) of the upcoming movie and Dusty shares a celebrity encounter of his own at the Atlanta Airport. SeatGeek: *: https://seatgeek.onelink.me/RrnK/NATE10 Use my code for 10% off your next SeatGeek order: https://seatgeek.onelink.me/RrnK/NATE10 Sponsored by SeatGeek. *Restrictions apply. Max $20 discount. BRUNT: bruntworkwear.com/NATE Get $10 Off at BRUNT with code NATE at bruntworkwear.com/NATE #Bruntpod #ad Helix: Helixsleep.com/NATE Go to helixsleep.com/nate for their Fourth of July sale and get 27% Off Sitewide. This is exclusive for our listeners of the Nateland Podcast.  DeleteMe: joindeleteme.com/NATE Get 20% off your DeleteMe plan when you go to joindeleteme.com/NATE and use promo code NATE at checkout.

BB Butters reads from forsooth to forte-piano.     The word of the episode is "forsooth".     Use my special link https://zen.ai/thedictionary to save 30% off your first month of any Zencastr paid plan.    Create your podcast today! #madeonzencastr     Theme music from Jonah Kraut https://jonahkraut.bandcamp.com/     Merchandising! https://www.teepublic.com/user/spejampar     "The Dictionary - Letter A" on YouTube   "The Dictionary - Letter B" on YouTube   "The Dictionary - Letter C" on YouTube   "The Dictionary - Letter D" on YouTube   "The Dictionary - Letter E" on YouTube   "The Dictionary - Letter F" on YouTube     Featured in a Top 10 Dictionary Podcasts list! https://blog.feedspot.com/dictionary_podcasts/     Backwards Talking on YouTube: https://www.youtube.com/playlist?list=PLmIujMwEDbgZUexyR90jaTEEVmAYcCzuq     https://linktr.ee/spejampar dictionarypod@gmail.com https://www.facebook.com/thedictionarypod/ https://www.threads.net/@dictionarypod https://twitter.com/dictionarypod https://www.instagram.com/dictionarypod/ https://www.patreon.com/spejampar https://www.tiktok.com/@spejampar 917-727-5757

Jurandir Filho, Thiago Siqueira, Rogério Montanare e Fernanda Schmölz batem um papo sobre como a inteligência artificial (IA) vem transformando rapidamente diversas indústrias, e o cinema está no centro dessa revolução. De algoritmos que recomendam filmes em plataformas de streaming até a geração de roteiros, vozes e rostos sintéticos, a IA está reconfigurando a forma como o entretenimento é produzido, distribuído e consumido.Um dos maiores pontos de discórdia gira em torno do uso de deepfakes e da replicação digital de atores - vivos ou mortos - sem o devido consentimento ou remuneração. Isso levantou debates éticos profundos sobre direitos de imagem, legado artístico e a própria natureza da atuação. Qual o futuro do cinema em tempos de IA? Qual o impacto social? Vai ser tudo diferente mesmo?- ASSINE O SALA VIP DO RAPADURACAST- Um podcast EXCLUSIVO do RapaduraCast toda semana! http://patreon.com/rapaduracast

Today on the podcast:- Matt is joined by his dad Ulysses "Gene" Forte for a special Father's Day weekend conversation on faith, forgiveness, fatherlessness and football. Have a question? Got a guest suggestion? Want to advertise with us? Email us - jason@sportsspectrum.comWATCH all of our podcast episodes on our YouTube page:https://www.youtube.com/SportsSpectrumMagazineSign up for our Sports Spectrum Magazine and receive 15% off a 1-year subscription by using the code PODCAST15https://www.theincrease.com/products/sports-spectrum-magazine Do you know Christ personally? Click below to learn how you can commit your life to Him.https://sportsspectrum.com/gospel/Have you heard our other Sports Spectrum podcasts?Sports Spectrum's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠What's Up Podcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠with Annabelle Hasselbeck - https://open.spotify.com/show/7CvX5oXnEuKIYI5GCVT7Hi?si=9c61982675f1413dSports Spectrum's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get in the Game Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ with Scott Linebrink -https://open.spotify.com/show/7CFPZVet3TcsSJMZqRHndI?si=d6599c85917146a7

The authors of the Pour Descisons collaboration series story by the podcast to chat about this years long idea that FINALLY has come to fruition. 

Episode 370: In this episode, we journey into the chilling case of Jesse Imeson—a man whose troubled past and violent crimes left a deep scar on Southwestern Ontario. In the summer of 2007, Imeson's name became synonymous with fear as he embarked on a deadly spree, taking three innocent lives. The victims were Carlos Rivera, 25, of Windsor and Helene Regier, 72, and her husband, Bill Regier, 73, near the community of Grand Bend. The discovery of the murders sparked a 12-day nationwide manhunt and led to the capture of the killer in Portage-du-Forte, Quebec, near the Ontario border. However, behind the headlines lies a story of trauma, addiction, and claims of childhood abuse that may have shaped the path to his horrific acts. Sources: ⁠Man who killed elderly couple and bartender has appeal rejected by Supreme Court | CBC News⁠⁠ Carlos Rivera - Search - Newspapers.com™ ⁠⁠Family of victims lash out as smirking killer gets life sentence⁠⁠ Supreme Court of Canada | 38467⁠⁠ Windsor murderer's claim of sexual abuse hits legal setback⁠⁠ 2021 ONSC 5289 (CanLII) | Imeson v. Maryvale | CanLII⁠⁠ 2018 ONCA 888 (CanLII) | Imeson v. Maryvale (Maryvale Adolescent and Family Services) | CanLII⁠⁠ 2017 ONSC 1906 (CanLII) | Imeson v. Maryvale | CanLII⁠⁠2016 ONSC 6020 (CanLII) | Imeson v Maryvale | CanLII⁠⁠ Murder suspect Jesse Imeson captured in Quebec⁠⁠Suspect in 3 Ontario slayings appears in Windsor court | CBC News⁠⁠ Ont. man pleads guilty in 3 'savage' slayings, sentenced to life | CBC News⁠⁠ LFP Archives: The hunt for, and truth about, spree killer Jesse Imeson⁠⁠ Inadmissible evidence could lead to new trial⁠⁠ Obituary of Helene Marie Regier | T. Harry Hoffman & Sons Funeral Home⁠⁠ So, why did he do it? - Grand Bend Strip community newspaper⁠⁠ America's Most Wanted joins hunt for Ontario fugitive | CBC News⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Dans cette nouvelle leçon, j'aborde une question que beaucoup d'indépendants et de freelances se posent :Comment se détacher de l'étiquette de “petit prestataire” pour être perçu comme un véritable partenaire stratégique ?Marine, fondatrice de l'agence Praesens, spécialisée dans la création de présentations à fort impact, m'a partagé ses doutes et ses difficultés à faire reconnaître la valeur de son travail et de son équipe, malgré la qualité livrée.Son cas est emblématique : elle n'est pas seule, elle travaille avec une équipe, et pourtant ses clients ne voient souvent qu'elle. Alors comment incarner un collectif ? Comment asseoir davantage de légitimité face à des clients qui vous perçoivent encore comme “la freelance sympa” ?Dans cet épisode, je vous propose des pistes concrètes pour bâtir une posture plus forte, affirmer votre valeur et créer un cadre relationnel plus respectueux et professionnel.Un épisode utile, percutant, que j'espère libérateur pour toutes celles et ceux qui se sentent trop petits… alors qu'ils ne le sont pas. Bonne écoute ! CHAPITRAGE 00:00 – Introduction : comment rompre avec l'étiquette de freelance02:34 – Présentation de Marine et de l'agence Praesens03:49 – Le vrai problème : être perçue comme freelance malgré une équipe07:19 – La solution simple pour faire comprendre qu'on est une vraie agence09:49 – La réunion de kick-off : l'arme fatale pour asseoir sa crédibilité12:09 – Ce deal que Marine a perdu… et ce qu'il lui a appris14:39 – Comment créer la bonne dynamique d'équipe dès le début d'un projet16:49 – Rattraper le coup avec les anciens clients : la stratégie douce18:29 – L'impact RH inattendu d'une réunion bien préparée19:59 – Même dans l'urgence, instaurer une réunion d'équipe, à distance20:49 – Où retrouver Marine et son agence pour booster vos présentations#freelance #entrepreneuriat #indépendant #consultant #prestataire #agencedecommunication #agencedecréation #valorisation #crédibilité #postureprofessionnelle #légitimité #relationclient #businessindépendant #confianceclient #clientfreelance #stratégieclient #partenairestratégique #présentationsimpactantes #agencedeprésentation #marineprésence #freelancestratégie #podcastbusiness #podcastentrepreneur #paulinelaigneau #leçonsdumercredi #monterenscale #boosterlavaleurNotes et références de l'épisode Pour retrouver Marine : Sur son site praesensSur LinkedInPour aller plus loin :La formation “Management et recrutement : ce qu'on n'apprend pas dans les livres”Vous pouvez consulter notre politique de confidentialité sur https://art19.com/privacy ainsi que la notice de confidentialité de la Californie sur https://art19.com/privacy#do-not-sell-my-info.

In this week's MBA Admissions podcast we began by discussing the recent events and activities in the news; specifically, we discussed the recent U.S. administration's decisions around visa interviews for international MBA students. These are, frankly, very disturbing times, which can seriously harm the MBA experience at for all candidates at top MBA programs in the United States. We are hoping that good sense will prevail, in the near future. Graham highlighted an admissions event he is helping to moderate in Paris this upcoming week, which includes ten of the top MBA programs from the United States. Signups are here: https://bit.ly/paristopmba Graham noted three articles that have been recently published on Clear Admit. The first focuses on the costs of applying to Business School, from application fees to test prep, campus visits, and beyond. The second focuses on which top MBA programs allow for test waivers of the GMAT and GRE. This list appears to grow each season. Graham then highlighted a report from Forte which Clear Admit covered, that illustrates significant gender pay gap differentials. Graham highlighted three Real Humans alumni spotlights, alums from UNC / Kenan Flagler working at their own business, Grantease, Rice / Jones working at McKinsey, and Emory / Goizueta working at Morgan Stanley. For this week, for the candidate profile review portion of the show, Alex selected two ApplyWire entries and one DecisionWire entry: This week's first MBA admissions candidate has a 675 GMAT and 3.5 GPA. They are from China, and we discussed whether they should apply in Round 1 or Round 2, and whether they should retake the GMAT. This week's second MBA candidate has outstanding numbers and is from Africa. We think they are likely to be a very strong candidate but need to work on their story and connect it to their goals. The final MBA candidate is deciding between Columbia and Yale, with a significant scholarship. This episode was recorded in Paris, France and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

On this episode of The P.A.S. Report Podcast, Professor Nicholas Giordano is joined by Stefano Forte, President of the New York Young Republican Club, to discuss the surge of political enthusiasm among young conservatives. Forte explains how the NYYRC is growing rapidly in one of the bluest states in the country and why young people, especially following the pandemic, are rejecting the radical leftist agenda. They also explore how Republicans are gaining ground in deep-blue cities, the disconnect of establishment GOP figures stuck in the past, and what the party must do to capitalize on the momentum. The conversation touches on Trump, grassroots organizing, and the urgency of political courage in today's culture war. Episode Highlights: Why young conservatives are energized and organizing in blue strongholds like New York How establishment Republicans still underestimate how far left Democrats have gone What the GOP must do to secure victories beyond 2024 and win over disaffected voters  

Will Forte is responsible for some of the most idiosyncratically bizarre characters in comedy history — and the funniest movie Pablo has ever seen. But to understand Forte's legend, you must peer behind the scenes of "MacGruber" and "SNL" (his mythical audition, included). With a little help from their mutual friends, Pablo goes inside the making of a cult classic... and that time Val Kilmer moved in. • Watch "The Four Seasons" on Netflix https://www.netflix.com/title/81750702 Learn more about your ad choices. Visit podcastchoices.com/adchoices